Xxxxxxxxx, M. H. et al. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 126, 1-14 (1994).
Xxxxxxxxx, M. H. et al. NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection. Exp Neurol 181, 47-56 (2003).
Xxxxxxxxx, M. Do you really need a blockchain? xxxxx://xxxxxxx.xxx/ xxxxxxxxxxxxx/status/787760892783894528
Xxxxxxxxx, M. T. Xxxxxx, X. Xxxxxxxxxx, X. X. XxXxxxx, and X.-X. Quisquater. Authentication protocols for ad hoc networks: taxonomy and research issues. In Q2SWinet ’05: Proceedings of the 1st ACM international workshop on Quality of service & security in wireless and mobile networks, pages 00–000, Xxx Xxxx, XX, XXX, 0000. ACM Press.
Xxxxxxxxx, M. S., Xxx, P. C., Xxxxxxxx, X. X., Xxxxxx, C. N. & Xxxxxxxxx-Xxxx, B. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infect. Dis. Ther. 8, 445–452 (2019). 87. Xxxx, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxx, X. X., Xxxx, X. & Xxxxxxxx, S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. 1 Agents Chemother. 49, 195–201 (2005). 88. Xxxx, X. X., Xxxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, M. R. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62, 780–783 (2008). 89. Xxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, X. X. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur. J. Clin. Pharmacol. 71, 707–714 (2015). 90. Xxxxxxxx, X. X. The ATTAIN trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 9, 281–289 (2014). 91. Xxxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X., Xxxxxxx, P., Xxxxxx, M., Xxxxxx, V. & Xxxxxxx, G. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob. Agents Chemother. 31, 1961–1966 (1987). 92. Xxxxxxxxx, X. & Xxxxxxxxx, X. X. Origin, structure, and activity in vitro and in vivo of dalbavancin.
Xxxxxxxxx, M. A.; Xxxxxxxx, X.X.; Xxxxxxxx, X.X. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu. Rev. Biomed. Eng. 2015, 17, 63–89, doi:10.1146/annurev-bioeng-071813-104938.
Xxxxxxxxx, M. A., Iucci, A., Guinea, F. & Xxxxxx Xxxx, X. X. Xxxxx moment formation and Kondo effect in defective graphene. Preprint arXiv 1207, 3135 (2012).
Xxxxxxxxx, M. E. (2006). Multilevel component analysis. British Journal of Mathematical and Statistical Psychology, 59, 301-320.
Xxxxxxxxx, M. A. (2017). Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet Infectious Diseases, 17(9), 909-948. United Nations. (2020). Sustainable development knowledge platform. Retrieved from: xxxxx://xxxxxxxxxxxxxxxxxxxxxx.xx.xxx/ United Nations Office for the Coordination of Humanitarian Affairs. (2016). Sierra Leone: Moyamba district profile. ReliefWeb. Retrieved from: xxxxx://xxxxxxxxx.xxx/report/sierra-leone/sierra-leone-moyamba-district- profile-18-december-2015 Xxxxxx, X. X., & Xxxxxx, X. X. (1958). Excreta Disposal for Rural Areas and Small Communities. Water1st International. (2019). F diagram. Retrieved from: xxxxx://xxxxx0xx.xxx/problem/f-diagram/ Xxxxxxx, X. X., & Xxxxx, F. (2018). Exploring the broader consequences of diarrhoeal diseases on child health. The Lancet Global Health, 6(3), e230-e231. Xxxxxx, X.X., Xxxxxx, X.X., & Xxxxxxx, S. (2012). ORS case study: Sierra Leone. Xxxxxx, S. C., & Xxxxxx, F. (2016). Access to sanitation and violence against women: evidence from Demographic Health Survey (DHS) data in Kenya. International journal of environmental health research, 26(3), 291-305. Xxxx, X., Xxxxxx, X. X., Xxxxxxx, M. C., Xxxxxxx, O., Xxxxxx, X., Xxxxxxx, X., ... & Xxxxx‐Ustün, A. (2018). Impact of drinking water, sanitation and handwashing with soap on childhood diarrhoeal disease: updated meta‐analysis and meta‐regression. Tropical medicine & international health, 23(5), 508-525. World Health Organization (WHO). (1992). Readings on diarrhoea: student manual. World Health Organization. World Health Organization (WHO). (2017). Diarrhoeal disease. Retrieved from: xxxxx://xxx.xxx.xxx/news-room/fact-sheets/detail/diarrhoeal-disease World Health Organization (WHO). (2019). Water, sanitation and hygiene in health care facilities: practical steps to achieve universal access to quality care. Xxxx, X., Xxxxxx, X., Xxxxxxxx, O., Xxxx, V., Xxxxxxxxxxxxx, M., & Xxxxxxxxx, G. (2018). Improving water, sanitation and hygiene practices, and housing quality to prevent diarrhea among under-five children in Nigeria. Tropical medicine and infectious disease, 3(2), 41. Appendix A – Full Survey PPI and Water, Sanitation, and Hygiene Practices Survey in Xxxxx, Xxxxxx Xxxxx, 0000 Conducted by Emory University for Children of the Nations Community Village name Household number [ ] [ ] [ ] Household has at least one child in it who attends ...
Xxxxxxxxx, M. A. as Chairman of Islamic Family Law Study Program, Magister Program (S2), Graduate Program of University Of Islamic Religion UIN Sunan Gunung Djati Bandung here in after referred to as THE FIRST PARTY. THE SECOND PARTY STUDY PROGRAM OF ISLAMIC FAMILY LAW, PASCASARJANA PROGRAM (S2), GRADUATE OF IAIN KENDARI Jl. Sultan Qaimuddin No. 17 Kendari, in this case represented by Dr. Xx. Xxxxxxxx, M.HI, as the Head of Study Program of Islamic Family Law, Pascasarjana Program (S2) IAIN Kendari, here in after referred to as THE SECOND PARTY. THE FIRST PARTY and THE SECOND PARTY in this Cooperation Agreement hereinafter referred to as PARTIES.
